Frontlight ResearchEarly access
CompletedNo phase
Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency
Key facts
- Who runs it
- Dr. Hatice Dönmez
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 31 people enrolled
- Started
- 15 Sept 2024
- Ended
- 15 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Virtual reality video watching
- Tablet video watching
- Record updated
- 9 June 2026
Who can take part
- Age
- 4 years to 11 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Being between the ages of 4-11
- Being followed up with the diagnosis of Primary Immunodeficiency for at least 6 months
- To accept participation in the study voluntarily
- No additional chronic disease other than primary immunodeficiency
Who cannot take part
- Organ failure is present
- Having a mental deficiency
- Having a disability to use VR Glasses
- Children with fever (|>37.5 C0)
- Children with severe dehydration
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In this study, it is aimed to investigate the effect of virtual reality and tablet video viewing intervention on pain and fear levels and vital signs of children during peripheral venous catheter placement for intravenous immunoglobulin (IVIG) administration.
The 2 groups in the trial
- Virtual reality groupTreatment being tested
Treatment: Virtual reality video watching
- Tablet groupExisting treatment, for comparison
Treatment: Tablet video watching
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect of Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency Applying Intravenous Immunoglobulin During Intravenous Access: A Crossover Randomized Controlled Trial
- Record updated
- 9 June 2026